15 Years of Anti-VEGF Treatment for NAMD: Success or Failure or Something in Between?

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2022 Jun 25

PMID 35752715

Authors

Usha Chakravarthy

Beatriz G Armendariz

Sascha Fauser

Affiliations

Soon will be listed here.

Citing Articles

Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis.

Wojciechowski P, Wdowiak M, Panek M, Lunk I, Carrasco J, Zhang X Ophthalmol Ther. 2025; .

PMID: 39994103 DOI: 10.1007/s40123-025-01098-y.

Photoreceptor Degeneration: More Than a Bystander in Age-Related Macular Degeneration.

Wubben T, Weh E, Besirli C Adv Exp Med Biol. 2025; 1468:27-31.

PMID: 39930168 DOI: 10.1007/978-3-031-76550-6_5.

Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab.

Rossi S, Gesualdo C, Marano E, Perrotta R, Trotta M, Del Giudice A Front Med (Lausanne). 2025; 11:1467160.

PMID: 39886454 PMC: 11780245. DOI: 10.3389/fmed.2024.1467160.

Resveratrol Supplementation in Wet AMD: Association With Fewer Intravitreal Injections and Reduced Macular Fibrosis.

Datseris I, Rouvas A, Tzanidaki M, Kardara M, Geros V, Gouliopoulos N Clin Ophthalmol. 2025; 19:217-225.

PMID: 39867345 PMC: 11762261. DOI: 10.2147/OPTH.S494595.

Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration.

Loewenstein A, Sylvanowicz M, Amoaku W, Aslam T, Cheung C, Eldem B Ophthalmol Ther. 2024; 14(1):211-228.

PMID: 39673040 PMC: 11724828. DOI: 10.1007/s40123-024-01061-3.

References

Jansen M, Krambeer C, Kermany D, Waters J, Tie W, Bahadorani S . Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina. 2018; 49(3):186-190. DOI: 10.3928/23258160-20180221-06. View

Mones J, Singh R, Bandello F, Souied E, Liu X, Gale R . Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. Ophthalmologica. 2019; 243(1):1-8. DOI: 10.1159/000502747. View

Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G . Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2017; 23(2):127-140. DOI: 10.1080/13548506.2016.1274040. View

Deng Y, Qiao L, Du M, Qu C, Wan L, Li J . Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022; 9(1):62-79. PMC: 8720701. DOI: 10.1016/j.gendis.2021.02.009. View

Jaffe G, Ying G, Toth C, Daniel E, Grunwald J, Martin D . Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2018; 126(2):252-260. PMC: 6462189. DOI: 10.1016/j.ophtha.2018.08.035. View

Evans R, Reeves B, Phillips D, Muldrew K, Rogers C, Harding S . Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial. Ophthalmology. 2020; 127(9):1191-1200. PMC: 7471837. DOI: 10.1016/j.ophtha.2020.03.020. View

Holz F, Tadayoni R, Beatty S, Berger A, Cereda M, Cortez R . Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2014; 99(2):220-6. PMC: 4316940. DOI: 10.1136/bjophthalmol-2014-305327. View

Gillies M, Campain A, Barthelmes D, Simpson J, Arnold J, Guymer R . Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology. 2015; 122(9):1837-45. DOI: 10.1016/j.ophtha.2015.05.010. View

Daniel E, Pan W, Ying G, Kim B, Grunwald J, Ferris 3rd F . Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2018; 125(7):1037-1046. PMC: 6015772. DOI: 10.1016/j.ophtha.2018.01.004. View

10.

Mones J, Srivastava S, Jaffe G, Tadayoni R, Albini T, Kaiser P . Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology. 2020; 128(7):1050-1059. DOI: 10.1016/j.ophtha.2020.11.011. View

11.

Daniel E, Toth C, Grunwald J, Jaffe G, Martin D, Fine S . Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013; 121(3):656-66. PMC: 3943618. DOI: 10.1016/j.ophtha.2013.10.019. View

12.

Grunwald J, Daniel E, Huang J, Ying G, Maguire M, Toth C . Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013; 121(1):150-161. PMC: 3892560. DOI: 10.1016/j.ophtha.2013.08.015. View

13.

Sadda S, Abdelfattah N, Lei J, Shi Y, Marion K, Morgenthien E . Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020; 127(10):1360-1370. DOI: 10.1016/j.ophtha.2020.03.031. View

14.

Bloch S, Larsen M, Munch I . Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol. 2012; 153(2):209-213.e2. DOI: 10.1016/j.ajo.2011.10.016. View

15.

Holekamp N, Campochiaro P, Chang M, Miller D, Pieramici D, Adamis A . Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021; 129(3):295-307. DOI: 10.1016/j.ophtha.2021.09.016. View

16.

Muether P, Hoerster R, Hermann M, Kirchhof B, Fauser S . Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012; 251(2):453-8. DOI: 10.1007/s00417-012-2038-0. View

17.

. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013; 309(19):2005-15. DOI: 10.1001/jama.2013.4997. View

18.

Casalino G, Stevenson M, Bandello F, Chakravarthy U . Tomographic Biomarkers Predicting Progression to Fibrosis in Treated Neovascular Age-Related Macular Degeneration: A Multimodal Imaging Study. Ophthalmol Retina. 2019; 2(5):451-461. DOI: 10.1016/j.oret.2017.08.019. View

19.

Grunwald J, Pistilli M, Ying G, Maguire M, Daniel E, Martin D . Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 122(4):809-16. PMC: 4372487. DOI: 10.1016/j.ophtha.2014.11.007. View

20.

Chakravarthy U, Harding S, Rogers C, Downes S, Lotery A, Culliford L . Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382(9900):1258-67. DOI: 10.1016/S0140-6736(13)61501-9. View